NSE: ANG • Promoter, FII, DII Holdings for Tickjournal
Promoter Holding70.60%
FII Holding0.00%
DII Holding0.00%
Public Holding26.18%
Total Shareholders6,273
As ofSept 2025
View the latest shareholding pattern of ANG Lifesciences (ANG) including promoter, FII, DII, and public holdings.
Track ANG ownership changes over time and document your investment thesis in Tickjournal — your personal trade journal.
(See ANG Lifesciences price earnings)
ANG Lifesciences (ANG) Shareholding Summary
Promoter holding remains unchanged at 70.60% in Sept 2025
FII/FPI holding remains unchanged at 0.00% in Sept 2025
DII holding remains unchanged at 0.00% in Sept 2025
Number of shareholders decreased from 6,400 to 6,273 in Sept 2025
ANG Quarterly Ownership Changes
Quarter-over-quarter changes for ANG Lifesciences from Jun 2025 to Sept 2025.
Promoter Holding Change
Jun 2025 to Sept 2025
No Change
FII Holding Change
Jun 2025 to Sept 2025
No Change
DII Holding Change
Jun 2025 to Sept 2025
No Change
Public Holding Change
Jun 2025 to Sept 2025
+0.07%
ANG Lifesciences (ANG) Quarterly Shareholding Trends
Visual breakdown of ANG ownership distribution over time. Learn more about ANG stock price history.
Promoter
FII
DII
Public
Government
Rising institutional holdings in ANG often correlate with improved fundamentals. Check out ANG market cap trends.
ANG Lifesciences (ANG) Shareholding Data
Download complete ANG ownership data for offline analysis. Discover ANG ex-dividend dates.
Period
Promoter (%)
FII (%)
DII (%)
Govt (%)
Public (%)
Other (%)
Total (%)
Shareholders
Sept 2025
70.60%
0.00%
0.00%
0.00%
26.18%
3.21%
99.99%
6,273
Jun 2025
70.60%
0.00%
0.00%
0.00%
26.11%
3.29%
100.00%
6,400
Mar 2025
70.60%
0.00%
0.00%
0.00%
26.11%
3.29%
100.00%
6,508
Dec 2024
70.60%
0.00%
0.00%
0.00%
25.92%
3.48%
100.00%
6,517
Sept 2024
70.60%
0.00%
0.00%
0.00%
25.45%
3.95%
100.00%
6,468
Jun 2024
70.60%
0.00%
0.00%
0.00%
25.48%
3.92%
100.00%
6,631
Mar 2024
70.60%
0.00%
0.00%
0.00%
25.62%
3.78%
100.00%
6,868
Dec 2023
70.60%
0.00%
0.00%
0.00%
25.29%
4.11%
100.00%
6,918
Sept 2023
70.60%
0.00%
0.00%
0.00%
26.09%
3.31%
100.00%
7,055
Jun 2023
70.60%
0.00%
0.00%
0.00%
26.23%
3.16%
99.99%
7,305
Mar 2023
70.60%
0.00%
0.00%
0.00%
26.13%
3.27%
100.00%
7,163
Dec 2022
71.15%
0.00%
0.00%
0.00%
25.56%
3.30%
100.01%
6,939
Sept 2022
71.15%
0.00%
0.00%
0.00%
25.76%
3.09%
100.00%
5,215
Jun 2022
71.15%
0.00%
0.00%
0.00%
25.66%
3.20%
100.01%
4,259
Mar 2022
71.14%
0.00%
0.00%
0.00%
25.87%
2.99%
100.00%
2,522
Dec 2021
71.09%
0.00%
0.00%
0.00%
26.62%
2.29%
100.00%
323
Sept 2021
71.07%
0.00%
0.00%
0.00%
25.53%
3.40%
100.00%
328
Mar 2021
71.01%
0.00%
0.00%
0.00%
19.94%
9.05%
100.00%
0
ANG promoter holding above 50% indicates strong insider confidence. Explore the ANG annual price range for detailed insights.
Quarter
Promoter (%)
FII (%)
DII (%)
Govt (%)
Public (%)
Other (%)
Total (%)
Shareholders
Sept 2025
70.60%
0.00%
0.00%
0.00%
26.18%
3.21%
99.99%
6,273
Jun 2025
70.60%
0.00%
0.00%
0.00%
26.11%
3.29%
100.00%
6,400
Mar 2025
70.60%
0.00%
0.00%
0.00%
26.11%
3.29%
100.00%
6,508
Dec 2024
70.60%
0.00%
0.00%
0.00%
25.92%
3.48%
100.00%
6,517
Sept 2024
70.60%
0.00%
0.00%
0.00%
25.45%
3.95%
100.00%
6,468
Jun 2024
70.60%
0.00%
0.00%
0.00%
25.48%
3.92%
100.00%
6,631
Mar 2024
70.60%
0.00%
0.00%
0.00%
25.62%
3.78%
100.00%
6,868
Dec 2023
70.60%
0.00%
0.00%
0.00%
25.29%
4.11%
100.00%
6,918
Sept 2023
70.60%
0.00%
0.00%
0.00%
26.09%
3.31%
100.00%
7,055
Jun 2023
70.60%
0.00%
0.00%
0.00%
26.23%
3.16%
99.99%
7,305
Mar 2023
70.60%
0.00%
0.00%
0.00%
26.13%
3.27%
100.00%
7,163
Dec 2022
71.15%
0.00%
0.00%
0.00%
25.56%
3.30%
100.01%
6,939
Quarterly data helps track institutional investment cycles.
Understanding ANG Lifesciences (ANG) Shareholding Pattern
ANG Lifesciences shareholding pattern reveals who owns ANG stock and how ownership changes over time. High promoter stakes in ANG often signal management confidence, while rising FII/DII holdings suggest growing institutional interest. Use Tickjournal to log these insights alongside your ANG trades. ANG price to book ratio
Combine ANG ownership analysis with price movements and financial performance for a complete investment picture. (See ANG Lifesciences quarterly earnings)